Abstract

INTRODUCTION: Neurological immune-related adverse events are a rare but potentially deadly complication after immune checkpoint inhibitor (ICI) treatment. As multiple sclerosis (MS) is an immune-mediated disease, it is unknown how ICI treatment may affect outcomes.

METHODS: We analyzed the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database for pembrolizumab, atezolizumab, nivolumab, ipilimumab, avelumab, and durvalumab 2 years prior their FDA approval until December 31, 2017, to include all cases with confirmed diagnosis/relapse of MS. We also included cases reported in the literature and a patient from our institution.

RESULTS: We identified 14 cases of MS with median age of presentation of 52 years. Indications for ICI included melanoma in 7 (36.36%) cases, non-small cell lung carcinoma in 2 (18.18%) cases, 1 case (9.09%) each of pleural mesothelioma, renal cell carcinoma, and colorectal cancer, and unreported in 2 (18.18%) cases. History of MS was confirmed in 8 (57.1%) cases. Median time to beginning of symptoms was 29 days with rapid disease progression; two patients died due to their relapse. Median time for symptom resolution was 8 weeks. Outcomes did not vary by comparing CTLA-4 and PD-1/PD-L1 inhibitors.

CONCLUSIONS: Reported MS relapses after ICI are rare, but the adverse events described include rapid neurologic progression and death. Larger and prospective studies are warranted to assess disability and long-term outcomes and outweigh the risks of starting immunotherapy in patients with MS.

Document Type

Review

Publication Date

10-2019

Notes/Citation Information

Published in Clinical and Translational Oncology, v. 21, issue 10.

© 2019 Springer Nature Switzerland AG.

This is a post-peer-review, pre-copyedit version of an article published in Clinical and Translational Oncology. The final authenticated version is available online at: https://doi.org/10.1007/s12094-019-02060-8

Digital Object Identifier (DOI)

https://doi.org/10.1007/s12094-019-02060-8

Funding Information

Ms. Jayswal was supported by the Biostatistics and Bioinformatics Shared Resource of the University of Kentucky Markey Cancer Center (P30CA177558).

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 85
    • Policy Citations: 1
  • Usage
    • Downloads: 1999
    • Abstract Views: 234
  • Captures
    • Readers: 127
  • Mentions
    • Blog Mentions: 1
    • News Mentions: 1
    • References: 2
see details

Share

COinS